Boehringer Sues Apotex To Protect Zantac Patent

Law360, New York (February 1, 2008, 12:00 AM EST) -- Boehringer Ingelheim Pharmaceuticals Inc. is suing Apotex Inc., claiming the Canadian company’s generic version of its over-the-counter heartburn treatment Zantac infringes a Boehringer patent.

In a complaint filed Thursday in the U.S. District Court for the District of Delaware, the German drugmaker’s U.S. subsidiary alleges that a recent abbreviated new drug application filed by Apotex with the U.S. Food and Drug Administration infringes a patent held by Boehringer that covers flavor-coated tablets.

The patent, U.S. Patent Number 5,098,715, is used in the manufacturing process of Boehringer’s...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.